MISSING DATA REPORT
Survey Data 2015 – 2019

ANZDATA

DATA

AUSTRALIA &
NEW ZEALAND

DIALYSIS & TRANSPLANT
REGISTRY

ANZDATA Registry

anzdata@anzdata.org.au

Abstract

The rates of non-response for ANZDATA survey items over the last 5 years

The tables shown here present the rates of non-response for ANZDATA survey items over the last 5 years, as N (%). The first row (Frequency) shows the number of patients that should have a response for the item. As rates of non-response have increased in recent years, individual hospital missing data reports will also be produced and supplied to units to highlight areas where reporting should improve. Rates can appear higher in the latest survey year as not all survey queries are received by the date of data lock.

ANZDATA Missing Data Report

The tables below show the rates of non-response for ANZDATA survey items over the last 5 years, as N (%). The first row (Frequency) shows the number of patients that should have a response for the item. As rates of non-response have increased in recent years, individual hospital missing data reports will also be produced and supplied to units to highlight areas where reporting should improve. Rates can appear higher in the latest survey year as not all survey queries are received by the date of data lock.

Table 1 Demographics

Variable	2015	2016	2017	2018	2019
Frequency	3343	3522	3759	3807	3904
Date of birth	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gender	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Country of birth	70 (2.1%)	108 (3.1%)	57 (1.5%)	67 (1.8%)	34 (0.9%)
Late referral seen <3 mths before 1st treatment	132 (3.9%)	158 (4.5%)	76 (2.0%)	88 (2.3%)	56 (1.4%)
Ethnicity 1	143 (4.3%)	200 (5.7%)	67 (1.8%)	124 (3.3%)	78 (2.0%)
Primary renal disease	85 (2.5%)	102 (2.9%)	58 (1.5%)	77 (2.0%)	27 (0.7%)
Was native kidney biopsied?	133 (4.0%)	232 (6.6%)	110 (2.9%)	100 (2.6%)	144 (3.7%)
Serum creatinine at entry	133 (4.0%)	141 (4.0%)	92 (2.4%)	100 (2.6%)	75 (1.9%)
Height at RRT entry (cm)	125 (3.7%)	190 (5.4%)	129 (3.4%)	115 (3.0%)	250 (6.4%)
Weight at RRT entry (kg)	70 (2.1%)	129 (3.7%)	67 (1.8%)	62 (1.6%)	131 (3.4%)
Smoking status at RRT entry	120 (3.6%)	174 (4.9%)	114 (3.0%)	103 (2.7%)	145 (3.7%)

Table 2 Comorbidities at RRT entry

Variable	2015	2016	2017	2018	2019
Frequency	3343	3522	3759	3807	3904
Postcode	334 (10.0%)	164 (4.7%)	64 (1.7%)	78 (2.0%)	85 (2.2%)
Chronic lung disease	31 (0.9%)	74 (2.1%)	39 (1.0%)	26 (0.7%)	110 (2.8%)
Coronary artery disease	32 (1.0%)	73 (2.1%)	39 (1.0%)	26 (0.7%)	110 (2.8%)
Peripheral vascular disease	32 (1.0%)	72 (2.0%)	39 (1.0%)	26 (0.7%)	109 (2.8%)
Cerebrovascular disease	31 (0.9%)	71 (2.0%)	37 (1.0%)	26 (0.7%)	111 (2.8%)
Diabetes	28 (0.8%)	68 (1.9%)	32 (0.9%)	30 (0.8%)	112 (2.9%)

ANZDATA Missing Data Report

Table 3 Comorbidities at survey date

Variable	2015	2016	2017	2018	2019
Frequency	30900	31971	33229	34385	35650
Postcode	3054 (9.9%)	1182 (3.7%)	399 (1.2%)	494 (1.4%)	405 (1.1%)
Chronic lung disease	132 (0.4%)	145 (0.5%)	135 (0.4%)	99 (0.3%)	178 (0.5%)
Coronary artery disease	130 (0.4%)	149 (0.5%)	132 (0.4%)	98 (0.3%)	177 (0.5%)
Peripheral vascular disease	130 (0.4%)	148 (0.5%)	134 (0.4%)	99 (0.3%)	178 (0.5%)
Cerebrovascular disease	131 (0.4%)	151 (0.5%)	134 (0.4%)	99 (0.3%)	180 (0.5%)
Diabetes	143 (0.5%)	152 (0.5%)	123 (0.4%)	100 (0.3%)	178 (0.5%)
Hepatitis C Antibody	159 (0.5%)	235 (0.7%)	197 (0.6%)	261 (0.8%)	325 (0.9%)

Table 4 Reason for change from CAPD to APD

Variable	2015	2016	2017	2018	2019
Frequency	702	611	623	639	619
Reason transfer from dialysis during survey	50 (7.1%)	54 (8.8%)	34 (5.5%)	26 (4.1%)	71 (11.5%)

Table 5 Reason for change from APD to CAPD

Variable	2015	2016	2017	2018	2019
Frequency	127	118	142	82	101
Reason transfer from dialysis during survey	14 (11.0%)	16 (13.6%)	18 (12.7%)	4 (4.9%)	12 (11.9%)

Table 6 Reason for change from PD to HD

Variable	2015	2016	2017	2018	2019
Frequency	844	838	808	809	758
Reason transfer from dialysis during survey	73 (8.6%)	90 (10.7%)	51 (6.3%)	39 (4.8%)	76 (10.0%)

Table 7 Reason for change from HD to PD

Variable	2015	2016	2017	2018	2019
Frequency	548	539	553	522	516
Reason transfer from dialysis during survey	48 (8.8%)	68 (12.6%)	33 (6.0%)	20 (3.8%)	34 (6.6%)

Table 8 Cause of death

Variable	2015	2016	2017	2018	2019
Frequency	2440	2556	2692	2587	2644
Cause of death	2 (0.1%)	21 (0.8%)	109 (4.0%)	56 (2.2%)	53 (2.0%)

ANZDATA Missing Data Report

Table 9 Dialysis data

Variable	2015	2016	2017	2018	2019
Frequency	18538	19024	19495	19867	20385
Dialysis type	300 (1.6%)	233 (1.2%)	158 (0.8%)	773 (3.9%)	949 (4.7%)
Dry Weight on last dialysis: End Survey, Transplantation or Death	1185 (6.4%)	1675 (8.8%)	955 (4.9%)	820 (4.1%)	1042 (5.1%)
Uncorrected calcium levels (mmol/l)	1151 (6.2%)	1547 (8.1%)	885 (4.5%)	801 (4.0%)	1125 (5.5%)
Phosphate levels (mmol/l)	1091 (5.9%)	1519 (8.0%)	866 (4.4%)	773 (3.9%)	1126 (5.5%)
Haemoglobin level nearest end Survey (g/l)	1084 (5.8%)	1514 (8.0%)	881 (4.5%)	774 (3.9%)	1121 (5.5%)
EPO Agent	1064 (5.7%)	1547 (8.1%)	894 (4.6%)	771 (3.9%)	1237 (6.1%)
Ferritin within last 3 months of Survey	1905 (10.3%)	2681 (14.1%)	1993 (10.2%)	1868 (9.4%)	1929 (9.5%)
% Saturation Iron (Transferrin Saturation) within last 3 months of survey	2399 (12.9%)	3315 (17.4%)	2380 (12.2%)	2452 (12.3%)	2621 (12.9%)

Table 10 Haemodialysis data

Variable	2015	2016	2017	2018	2019
Frequency	14898	15376	15821	16203	16747
Dialyser brand, model, membrane, surface area	977 (6.6%)	1087 (7.1%)	788 (5.0%)	676 (4.2%)	1022 (6.1%)
Blood flow rate (mls/min)	976 (6.6%)	1357 (8.8%)	788 (5.0%)	685 (4.2%)	1010 (6.0%)
Frequency of dialysis per week	960 (6.4%)	1331 (8.7%)	762 (4.8%)	650 (4.0%)	980 (5.9%)
Hours per session	964 (6.5%)	1351 (8.8%)	786 (5.0%)	678 (4.2%)	1000 (6.0%)
Adequacy method (urea reduction or Kt/V)	2829 (19.0%)	3541 (23.0%)	2964 (18.7%)	2960 (18.3%)	3491 (20.8%)
Adequacy value (Urea reduction ratio % or Kt/V value on HD)	2862 (19.2%)	3427 (22.3%)	2985 (18.9%)	2960 (18.3%)	3491 (20.8%)
Vascular access in use at last haemodialysis	1042 (7.0%)	1394 (9.1%)	808 (5.1%)	698 (4.3%)	1167 (7.0%)

Table 11 Access at first HD

Variable	2015	2016	2017	2018	2019
Frequency	2741	2902	3105	3146	3285
Vascular access in use at first haemodialysis	228 (8.3%)	227 (7.8%)	110 (3.5%)	89 (2.8%)	135 (4.1%)

Table 12 Peritoneal dialysis data

Variable	2015	2016	2017	2018	2019
Frequency	4772	4789	4790	4770	4698
Type of Peritoneal Connection System	401 (8.4%)	414 (8.6%)	256 (5.3%)	189 (4.0%)	359 (7.6%)
Total volume weekly exchanges - All PD	372 (7.8%)	574 (12.0%)	250 (5.2%)	168 (3.5%)	424 (9.0%)
PD Solution Glucose	355 (7.4%)	448 (9.4%)	246 (5.1%)	156 (3.3%)	500 (10.6%)
PD Solution Iodextrin	361 (7.6%)	446 (9.3%)	247 (5.2%)	156 (3.3%)	518 (11.0%)
PD Solution Low GDP (either Lactate or Bicarbonate)	376 (7.9%)	447 (9.3%)	243 (5.1%)	158 (3.3%)	503 (10.7%)
Creatinine Clearance (litres per week)	1652 (34.6%)	1798 (37.5%)	1578 (32.9%)	1463 (30.7%)	1622 (34.5%)
Dialysate Only Weekly Kt/V value on PD	1654 (34.7%)	1798 (37.5%)	1568 (32.7%)	1472 (30.9%)	1613 (34.3%)
Residual renal function (creatinine clearance - GFR)	1710 (35.8%)	1832 (38.3%)	1612 (33.7%)	1482 (31.1%)	1636 (34.8%)

ANZDATA Missing Data Report

Table 13 Peritoneal dialysis PET test

Variable	2015	2016	2017	2018	2019
Frequency	1357	1392	1408	1388	1341
PET test for PD-within first 6 mths starting?	1258 (92.7%)	1325 (95.2%)	1319 (93.7%)	1252 (90.2%)	942 (70.2%)

Table 14 Peritonitis episodes data

Variable	2015	2016	2017	2018	2019
Frequency	1158	1096	1081	1139	910
Was this a relapse or recurrence of peritonitis?	114 (9.8%)	154 (14.1%)	140 (13.0%)	107 (9.4%)	118 (13.0%)
Technique at time of infection	64 (5.5%)	62 (5.7%)	50 (4.6%)	40 (3.5%)	106 (11.6%)
Antifungal Therapy?	148 (12.8%)	186 (17.0%)	167 (15.4%)	108 (9.5%)	179 (19.7%)
Name of initial regimen first antibiotic given	123 (10.6%)	147 (13.4%)	139 (12.9%)	101 (8.9%)	117 (12.9%)
Name of final regimen first antibiotic given	155 (13.4%)	172 (15.7%)	156 (14.4%)	127 (11.2%)	185 (20.3%)
Glucose PD Solution at time of infection?	187 (16.1%)	204 (18.6%)	186 (17.2%)	145 (12.7%)	149 (16.4%)
Icodextrin PD Solution at time of infection?	192 (16.6%)	214 (19.5%)	188 (17.4%)	145 (12.7%)	148 (16.3%)
Low GDP PD Solution (either Lactate or Bicarbonate) at time of infection?	169 (14.6%)	201 (18.3%)	205 (19.0%)	165 (14.5%)	153 (16.8%)
Was patient hospitalised overnight?	129 (11.1%)	155 (14.1%)	138 (12.8%)	104 (9.1%)	121 (13.3%)
Was catheter removed?	119 (10.3%)	158 (14.4%)	132 (12.2%)	105 (9.2%)	125 (13.7%)
Did patient have interim haemodialysis?	132 (11.4%)	173 (15.8%)	153 (14.2%)	132 (11.6%)	141 (15.5%)
Did patient transfer to permanent haemodialysis?	128 (11.1%)	168 (15.3%)	154 (14.2%)	129 (11.3%)	128 (14.1%)

Table 15 Transplant baseline data

Variable	2015	2016	2017	2018	2019
Frequency	1092	1257	1290	1317	1315
Recipient CMV antibody status	46 (4.2%)	130 (10.3%)	55 (4.3%)	15 (1.1%)	37 (2.8%)
Recipient EBV antibody status	52 (4.8%)	139 (11.1%)	53 (4.1%)	15 (1.1%)	40 (3.0%)
Donor source	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Donor age	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Donor sex	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Total ischaemia (to nearest hour)	62 (5.7%)	139 (11.1%)	78 (6.0%)	33 (2.5%)	100 (7.6%)
Immediate function	35 (3.2%)	117 (9.3%)	34 (2.6%)	24 (1.8%)	34 (2.6%)
HLA-A mismatch	23 (2.1%)	28 (2.2%)	23 (1.8%)	6 (0.5%)	11 (0.8%)
HLA-B mismatch	22 (2.0%)	28 (2.2%)	23 (1.8%)	6 (0.5%)	11 (0.8%)
HLA-DR mismatch	22 (2.0%)	28 (2.2%)	23 (1.8%)	6 (0.5%)	11 (0.8%)
HLA-DQ mismatch	581 (53.2%)	566 (45.0%)	538 (41.7%)	490 (37.2%)	197 (15.0%)
Donor blood group	13 (1.2%)	14 (1.1%)	1 (0.1%)	2 (0.2%)	0 (0.0%)
Recipient blood group	12 (1.1%)	8 (0.6%)	0 (0.0%)	1 (0.1%)	0 (0.0%)
Current (At transplant) antibodies	72 (6.6%)	80 (6.4%)	68 (5.3%)	45 (3.4%)	1101 (83.7%)
MatchPRA	73 (6.7%)	87 (6.9%)	120 (9.3%)	241 (18.3%)	12 (0.9%)

ANZDATA Missing Data Report

Table 16 Cause of graft failure

Variable	2015	2016	2017	2018	2019
Frequency	313	295	318	364	306
Cause of graft failure	0 (0.0%)	7 (2.4%)	38 (11.9%)	26 (7.1%)	54 (17.6%)

Table 17 Rejection data

Variable	2015	2016	2017	2018	2019
Frequency	481	425	540	472	400
Was a biopsy performed?	9 (1.9%)	3 (0.7%)	2 (0.4%)	2 (0.4%)	2 (0.5%)
Response of this rejection to treatment	20 (4.2%)	19 (4.5%)	40 (7.4%)	57 (12.1%)	26 (6.5%)
Primary treatment of rejection	6 (1.2%)	12 (2.8%)	10 (1.9%)	19 (4.0%)	2 (0.5%)

Table 18 Rejection data if biopsy performed

Variable	2015	2016	2017	2018	2019
Frequency	463	409	528	461	393
If biopsy is Yes ?Cellular	5 (1.1%)	10 (2.4%)	16 (3.0%)	23 (5.0%)	3 (0.8%)
If biopsy is Yes ?Glomerular	9 (1.9%)	14 (3.4%)	16 (3.0%)	19 (4.1%)	13 (3.3%)
If biopsy is Yes ?Vascular	8 (1.7%)	18 (4.4%)	23 (4.4%)	23 (5.0%)	11 (2.8%)
Humoral Rejection	15 (3.2%)	20 (4.9%)	16 (3.0%)	27 (5.9%)	25 (6.4%)
If biopsy is Yes and Banff g is known	58 (12.5%)	60 (14.7%)	39 (7.4%)	35 (7.6%)	21 (5.3%)
If biopsy is Yes and Banff i is known	58 (12.5%)	55 (13.4%)	38 (7.2%)	35 (7.6%)	18 (4.6%)
If biopsy is Yes and Banff t is known	57 (12.3%)	55 (13.4%)	38 (7.2%)	33 (7.2%)	18 (4.6%)
If biopsy is Yes and Banff v is known	60 (13.0%)	62 (15.2%)	47 (8.9%)	39 (8.5%)	20 (5.1%)

Table 19 Rejection data if biopsy not performed

Variable	2015	2016	2017	2018	2019
Frequency	9	13	10	9	5
Likelihood of rejection if biopsy not performed	1 (11.1%)	1 (7.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 20 Transplant follow-up data, 0 months

Variable	2015	2016	2017	2018	2019
Frequency	1114	1279	1307	1345	1329
Weight	61 (5.5%)	133 (10.4%)	62 (4.7%)	62 (4.6%)	76 (5.7%)
Drug data	43 (3.9%)	118 (9.2%)	55 (4.2%)	68 (5.1%)	45 (3.4%)

Table 21 Transplant follow-up data, 1 months

Variable	2015	2016	2017	2018	2019
Frequency	1055	1266	1303	1326	1319
Weight	98 (9.3%)	136 (10.7%)	44 (3.4%)	48 (3.6%)	41 (3.1%)
Serum creatinine	44 (4.2%)	113 (8.9%)	40 (3.1%)	38 (2.9%)	33 (2.5%)
Drug data	37 (3.5%)	97 (7.7%)	28 (2.1%)	24 (1.8%)	32 (2.4%)

Table 22 Transplant follow-up data, 2 months

Variable	2015	2016	2017	2018	2019
Frequency	1061	1214	1309	1332	1314
Weight	113 (10.7%)	172 (14.2%)	82 (6.3%)	54 (4.1%)	66 (5.0%)
Serum creatinine	42 (4.0%)	129 (10.6%)	51 (3.9%)	35 (2.6%)	52 (4.0%)
Drug data	35 (3.3%)	114 (9.4%)	46 (3.5%)	22 (1.7%)	60 (4.6%)

Table 23 Transplant follow-up data, 3 months

Variable	2015	2016	2017	2018	2019
Frequency	1053	1191	1296	1308	1279
Weight	123 (11.7%)	169 (14.2%)	134 (10.3%)	82 (6.3%)	95 (7.4%)
Serum creatinine	45 (4.3%)	114 (9.6%)	80 (6.2%)	53 (4.1%)	76 (5.9%)
Drug data	37 (3.5%)	106 (8.9%)	74 (5.7%)	41 (3.1%)	79 (6.2%)

Table 24 Transplant follow-up data, 6 months

Variable	2015	2016	2017	2018	2019
Frequency	987	1184	1270	1285	1293
Weight	147 (14.9%)	216 (18.2%)	192 (15.1%)	153 (11.9%)	170 (13.1%)
Serum creatinine	61 (6.2%)	139 (11.7%)	97 (7.6%)	110 (8.6%)	134 (10.4%)
Drug data	54 (5.5%)	137 (11.6%)	107 (8.4%)	101 (7.9%)	140 (10.8%)

Table 25 Transplant follow-up data, 12 months

Variable	2015	2016	2017	2018	2019
Frequency	1007	1048	1217	1253	1289
Weight	138 (13.7%)	175 (16.7%)	147 (12.1%)	154 (12.3%)	194 (15.1%)
Serum creatinine	48 (4.8%)	118 (11.3%)	86 (7.1%)	114 (9.1%)	147 (11.4%)
Drug data	45 (4.5%)	106 (10.1%)	83 (6.8%)	109 (8.7%)	145 (11.2%)

Table 26 Transplant follow-up data, 24 months

Variable	2015	2016	2017	2018	2019
Frequency	939	989	1016	1180	1220
Weight	114 (12.1%)	162 (16.4%)	133 (13.1%)	166 (14.1%)	194 (15.9%)
Serum creatinine	47 (5.0%)	88 (8.9%)	82 (8.1%)	121 (10.3%)	142 (11.6%)
Drug data	45 (4.8%)	84 (8.5%)	81 (8.0%)	117 (9.9%)	144 (11.8%)

Table 27 Transplant follow-up data, 36 months

Variable	2015	2016	2017	2018	2019
Frequency	871	905	957	989	1145
Weight	115 (13.2%)	128 (14.1%)	149 (15.6%)	134 (13.5%)	201 (17.6%)
Serum creatinine	41 (4.7%)	80 (8.8%)	88 (9.2%)	98 (9.9%)	139 (12.1%)
Drug data	41 (4.7%)	78 (8.6%)	87 (9.1%)	98 (9.9%)	140 (12.2%)

Table 28 Transplant follow-up data, 60 months

Variable	2015	2016	2017	2018	2019
Frequency	801	810	808	844	888
Weight	128 (16.0%)	163 (20.1%)	134 (16.6%)	132 (15.6%)	177 (19.9%)
Serum creatinine	46 (5.7%)	101 (12.5%)	68 (8.4%)	94 (11.1%)	129 (14.5%)
Drug data	40 (5.0%)	91 (11.2%)	67 (8.3%)	95 (11.3%)	136 (15.3%)

Table 29 Transplant follow-up data, 84 months

Variable	2015	2016	2017	2018	2019
Frequency	706	724	742	731	755
Weight	93 (13.2%)	142 (19.6%)	123 (16.6%)	112 (15.3%)	149 (19.7%)
Serum creatinine	43 (6.1%)	90 (12.4%)	79 (10.6%)	84 (11.5%)	93 (12.3%)
Drug data	42 (5.9%)	76 (10.5%)	79 (10.6%)	86 (11.8%)	105 (13.9%)

Table 30 Transplant follow-up data, 120 months

Variable	2015	2016	2017	2018	2019
Frequency	471	490	497	598	635
Weight	56 (11.9%)	84 (17.1%)	74 (14.9%)	105 (17.6%)	115 (18.1%)
Serum creatinine	30 (6.4%)	48 (9.8%)	46 (9.3%)	68 (11.4%)	79 (12.4%)
Drug data	28 (5.9%)	40 (8.2%)	50 (10.1%)	71 (11.9%)	93 (14.6%)

Table 31 Transplant follow-up data, 180 months

Variable	2015	2016	2017	2018	2019
Frequency	321	304	369	314	378
Weight	45 (14.0%)	62 (20.4%)	51 (13.8%)	58 (18.5%)	83 (22.0%)
Serum creatinine	22 (6.9%)	41 (13.5%)	31 (8.4%)	41 (13.1%)	56 (14.8%)
Drug data	24 (7.5%)	40 (13.2%)	38 (10.3%)	43 (13.7%)	61 (16.1%)

Table 32 Transplant follow-up data, 240 months

Variable	2015	2016	2017	2018	2019
Frequency	161	184	197	185	200
Weight	25 (15.5%)	31 (16.8%)	34 (17.3%)	35 (18.9%)	40 (20.0%)
Serum creatinine	12 (7.5%)	20 (10.9%)	24 (12.2%)	25 (13.5%)	27 (13.5%)
Drug data	12 (7.5%)	22 (12.0%)	26 (13.2%)	25 (13.5%)	30 (15.0%)

Table 33 Transplant follow-up data, 300 months

Variable	2015	2016	2017	2018	2019
Frequency	84	96	94	77	96
Weight	14 (16.7%)	16 (16.7%)	18 (19.1%)	17 (22.1%)	21 (21.9%)
Serum creatinine	11 (13.1%)	9 (9.4%)	11 (11.7%)	9 (11.7%)	12 (12.5%)
Drug data	5 (6.0%)	8 (8.3%)	15 (16.0%)	10 (13.0%)	14 (14.6%)

Table 34 Transplant follow-up data, 360 months

Variable	2015	2016	2017	2018	2019
Frequency	39	47	44	55	54
Weight	9 (23.1%)	11 (23.4%)	8 (18.2%)	11 (20.0%)	10 (18.5%)
Serum creatinine	4 (10.3%)	7 (14.9%)	8 (18.2%)	6 (10.9%)	6 (11.1%)
Drug data	3 (7.7%)	8 (17.0%)	4 (9.1%)	6 (10.9%)	8 (14.8%)

Table 35 Transplant follow-up data, 420 months

Variable	2015	2016	2017	2018	2019
Frequency	19	29	28	20	25
Weight	5 (26.3%)	9 (31.0%)	7 (25.0%)	7 (35.0%)	6 (24.0%)
Serum creatinine	2 (10.5%)	5 (17.2%)	4 (14.3%)	3 (15.0%)	4 (16.0%)
Drug data	2 (10.5%)	5 (17.2%)	4 (14.3%)	3 (15.0%)	6 (24.0%)

Table 36 Transplant follow-up data, 480 months

Variable	2015	2016	2017	2018	2019
Frequency	7	9	15	16	14
Weight	1 (14.3%)	1 (11.1%)	2 (13.3%)	5 (31.3%)	3 (21.4%)
Serum creatinine	0 (0.0%)	0 (0.0%)	1 (6.7%)	3 (18.8%)	2 (14.3%)
Drug data	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (18.8%)	2 (14.3%)

Table 37 Transplant follow-up data, 540 months

Variable	2015	2016	2017	2018	2019
Frequency	5	6	0	2	4
Weight	3 (60.0%)	2 (33.3%)	-	0 (0.0%)	1 (25.0%)
Serum creatinine	1 (20.0%)	2 (33.3%)	-	0 (0.0%)	0 (0.0%)
Drug data	1 (20.0%)	2 (33.3%)	-	0 (0.0%)	1 (25.0%)

Table 38 Transplant follow-up data, 600 months

Variable	2015	2016	2017	2018	2019
Frequency	0	0	0	0	0
Weight	-	-	-	-	-
Serum creatinine	-	-	-	-	-
Drug data	-	-	-	-	-

ANZDATA Missing Data Report

Table 39 Paediatric assessment at entry

Variable	2015	2016	2017	2018	2019
Frequency	36	40	48	45	31
Height	0 (0.0%)	1 (2.5%)	2 (4.2%)	1 (2.2%)	1 (3.2%)
Weight	0 (0.0%)	1 (2.5%)	2 (4.2%)	0 (0.0%)	1 (3.2%)
Paediatric Assessment at end of each Survey	2 (5.6%)	2 (5.0%)	2 (4.2%)	0 (0.0%)	2 (6.5%)

Table 40 Paediatric assessment at survey

Variable	2015	2016	2017	2018	2019
Frequency	332	340	352	361	355
Height	21 (6.3%)	22 (6.5%)	28 (8.0%)	26 (7.2%)	22 (6.2%)
Weight	16 (4.8%)	20 (5.9%)	28 (8.0%)	26 (7.2%)	20 (5.6%)
Paediatric Assessment at end of each Survey	19 (5.7%)	22 (6.5%)	25 (7.1%)	25 (6.9%)	20 (5.6%)

Table 41 Parenthood data

Variable	2015	2016	2017	2018	2019
Frequency	74	53	60	50	41
Pregnancy outcome	1 (1.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Neonatal survival	8 (10.8%)	13 (24.5%)	9 (15.0%)	9 (18.0%)	4 (9.8%)
Gestational age (best clinical estimate, weeks)	73 (98.6%)	52 (98.1%)	37 (61.7%)	14 (28.0%)	7 (17.1%)
Diabetes	74 (100.0%)	52 (98.1%)	30 (50.0%)	19 (38.0%)	19 (46.3%)
Hypertension (Somanz 2014 definition)	74 (100.0%)	52 (98.1%)	33 (55.0%)	27 (54.0%)	22 (53.7%)
CYA Immunosuppression at conception	74 (100.0%)	52 (98.1%)	36 (60.0%)	24 (48.0%)	7 (17.1%)
AZA Immunosuppression at conception	74 (100.0%)	52 (98.1%)	34 (56.7%)	21 (42.0%)	6 (14.6%)
Pred Immunosuppression at conception	74 (100.0%)	51 (96.2%)	34 (56.7%)	21 (42.0%)	6 (14.6%)
Tac Immunosuppression at conception	74 (100.0%)	51 (96.2%)	33 (55.0%)	22 (44.0%)	6 (14.6%)
MMF Immunosuppression at conception	74 (100.0%)	51 (96.2%)	35 (58.3%)	25 (50.0%)	7 (17.1%)
Sirol Immunosuppression at conception	74 (100.0%)	52 (98.1%)	36 (60.0%)	26 (52.0%)	8 (19.5%)
Other Immunosuppression at conception	74 (100.0%)	52 (98.1%)	38 (63.3%)	28 (56.0%)	8 (19.5%)
Labour type	74 (100.0%)	51 (96.2%)	38 (63.3%)	26 (52.0%)	23 (56.1%)
Delivery type	74 (100.0%)	52 (98.1%)	38 (63.3%)	26 (52.0%)	22 (53.7%)
Congenital condition present?	74 (100.0%)	51 (96.2%)	35 (58.3%)	17 (34.0%)	4 (9.8%)

Table 42 Parenthood birthweight data

Variable	2015	2016	2017	2018	2019
Frequency	68	43	55	46	38
Weight at birth (gms)	18 (26.5%)	8 (18.6%)	11 (20.0%)	8 (17.4%)	6 (15.8%)

Table 43 Parenthood creatinine prior to conception

Variable	2015	2016	2017	2018	2019
Frequency	20	16	19	14	11
Creatinine prior to conception (umol/L)	3 (15.0%)	2 (12.5%)	3 (15.8%)	1 (7.1%)	0 (0.0%)

Table 44 Parenthood creatinine post delivery

Variable	2015	2016	2017	2018	2019
Frequency	19	16	19	14	9
Creatinine 3 months post delivery (umol/L)	5 (26.3%)	2 (12.5%)	5 (26.3%)	2 (14.3%)	2 (22.2%)

Table 45 Non-skin cancer data

Variable	2015	2016	2017	2018	2019
Frequency	674	642	571	572	503
Cancer type	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Primary site of cancer category	15 (2.2%)	16 (2.5%)	12 (2.1%)	26 (4.5%)	18 (3.6%)
Cancer staging code	31 (4.6%)	37 (5.8%)	47 (8.2%)	68 (11.9%)	55 (10.9%)
Type 1st treatment	32 (4.7%)	37 (5.8%)	42 (7.4%)	69 (12.1%)	63 (12.5%)